Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Berubitinib + PLB1004 as first-line treatment for EGFR-mutant, MET-abnormal advanced or metastatic non-small cell lung cancer
CTR20241781Phase 2Active
- Sponsor
- Anshi Pharma
- Start
- Aug 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vebreltinib, andamertinib, osimertinib in non-small cell lung cancer (NSCLC), sponsored by Anshi Pharma. Started Aug 2024; status: active.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20241781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241781.